EP0400083A1 - Trophoblastin-isoformen, durch diese isoformen konstituierte interferone, verfahren zu deren erhalt und deren verwendung - Google Patents
Trophoblastin-isoformen, durch diese isoformen konstituierte interferone, verfahren zu deren erhalt und deren verwendungInfo
- Publication number
- EP0400083A1 EP0400083A1 EP19890903762 EP89903762A EP0400083A1 EP 0400083 A1 EP0400083 A1 EP 0400083A1 EP 19890903762 EP19890903762 EP 19890903762 EP 89903762 A EP89903762 A EP 89903762A EP 0400083 A1 EP0400083 A1 EP 0400083A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- leu
- asp
- gln
- arg
- glu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000001708 Protein Isoforms Human genes 0.000 title claims abstract description 70
- 108010029485 Protein Isoforms Proteins 0.000 title claims abstract description 70
- 102000014150 Interferons Human genes 0.000 title description 40
- 108010050904 Interferons Proteins 0.000 title description 40
- 229940047124 interferons Drugs 0.000 title description 23
- 238000004519 manufacturing process Methods 0.000 title description 3
- 101710144961 Interferon tau-1 Proteins 0.000 claims abstract description 104
- 101710144950 Interferon tau-2 Proteins 0.000 claims abstract description 104
- 101710144962 Interferon tau-3 Proteins 0.000 claims abstract description 104
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims abstract description 13
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 239000002299 complementary DNA Substances 0.000 claims description 35
- 108020004999 messenger RNA Proteins 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 24
- 210000002257 embryonic structure Anatomy 0.000 claims description 21
- 230000000840 anti-viral effect Effects 0.000 claims description 18
- 210000001161 mammalian embryo Anatomy 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 239000000872 buffer Substances 0.000 claims description 14
- 239000001963 growth medium Substances 0.000 claims description 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 239000000523 sample Substances 0.000 claims description 13
- 239000002773 nucleotide Substances 0.000 claims description 11
- 210000002966 serum Anatomy 0.000 claims description 11
- 108020004635 Complementary DNA Proteins 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 239000002243 precursor Substances 0.000 claims description 10
- 230000035935 pregnancy Effects 0.000 claims description 10
- 241000282414 Homo sapiens Species 0.000 claims description 9
- 108091034057 RNA (poly(A)) Proteins 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 238000013519 translation Methods 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000002955 isolation Methods 0.000 claims description 7
- 239000002609 medium Substances 0.000 claims description 7
- 102000006992 Interferon-alpha Human genes 0.000 claims description 6
- 108010047761 Interferon-alpha Proteins 0.000 claims description 6
- 238000010367 cloning Methods 0.000 claims description 6
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000001028 anti-proliverative effect Effects 0.000 claims description 5
- 238000012512 characterization method Methods 0.000 claims description 5
- 238000004587 chromatography analysis Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000010828 elution Methods 0.000 claims description 5
- 230000002519 immonomodulatory effect Effects 0.000 claims description 5
- 230000001900 immune effect Effects 0.000 claims description 5
- 238000001114 immunoprecipitation Methods 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- PXAFHUATEHLECW-GUBZILKMSA-N Gln-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N PXAFHUATEHLECW-GUBZILKMSA-N 0.000 claims description 4
- UUYBFNKHOCJCHT-VHSXEESVSA-N Gly-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)CN UUYBFNKHOCJCHT-VHSXEESVSA-N 0.000 claims description 4
- KAFOIVJDVSZUMD-UHFFFAOYSA-N Leu-Gln-Gln Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)NC(CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-UHFFFAOYSA-N 0.000 claims description 4
- QIJVAFLRMVBHMU-KKUMJFAQSA-N Lys-Asp-Phe Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O QIJVAFLRMVBHMU-KKUMJFAQSA-N 0.000 claims description 4
- 108010071390 Serum Albumin Proteins 0.000 claims description 4
- 102000007562 Serum Albumin Human genes 0.000 claims description 4
- 230000009471 action Effects 0.000 claims description 4
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 108010018006 histidylserine Proteins 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000013612 plasmid Substances 0.000 claims description 4
- 238000012546 transfer Methods 0.000 claims description 4
- 230000035899 viability Effects 0.000 claims description 4
- 238000005349 anion exchange Methods 0.000 claims description 3
- 238000010804 cDNA synthesis Methods 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000010276 construction Methods 0.000 claims description 3
- 238000011161 development Methods 0.000 claims description 3
- 230000018109 developmental process Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000009396 hybridization Methods 0.000 claims description 3
- 230000029860 luteolysis Effects 0.000 claims description 3
- SVBXIUDNTRTKHE-CIUDSAMLSA-N Ala-Arg-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O SVBXIUDNTRTKHE-CIUDSAMLSA-N 0.000 claims description 2
- MEFILNJXAVSUTO-JXUBOQSCSA-N Ala-Leu-Thr Chemical compound C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O MEFILNJXAVSUTO-JXUBOQSCSA-N 0.000 claims description 2
- FSXDWQGEWZQBPJ-HERUPUMHSA-N Ala-Trp-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)O)C(=O)O)N FSXDWQGEWZQBPJ-HERUPUMHSA-N 0.000 claims description 2
- YNSGXDWWPCGGQS-YUMQZZPRSA-N Arg-Gly-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O YNSGXDWWPCGGQS-YUMQZZPRSA-N 0.000 claims description 2
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 claims description 2
- YVXRYLVELQYAEQ-SRVKXCTJSA-N Asn-Leu-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC(=O)N)N YVXRYLVELQYAEQ-SRVKXCTJSA-N 0.000 claims description 2
- HRGGPWBIMIQANI-GUBZILKMSA-N Asp-Gln-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HRGGPWBIMIQANI-GUBZILKMSA-N 0.000 claims description 2
- WSXDIZFNQYTUJB-SRVKXCTJSA-N Asp-His-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O WSXDIZFNQYTUJB-SRVKXCTJSA-N 0.000 claims description 2
- MVRGBQGZSDJBSM-GMOBBJLQSA-N Asp-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(=O)O)N MVRGBQGZSDJBSM-GMOBBJLQSA-N 0.000 claims description 2
- IQCJOIHDVFJQFV-LKXGYXEUSA-N Asp-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(=O)O)N)O IQCJOIHDVFJQFV-LKXGYXEUSA-N 0.000 claims description 2
- OJQJUQUBJGTCRY-WFBYXXMGSA-N Cys-Ala-Trp Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)O)NC(=O)[C@H](CS)N OJQJUQUBJGTCRY-WFBYXXMGSA-N 0.000 claims description 2
- UGPCUUWZXRMCIJ-KKUMJFAQSA-N Cys-Tyr-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CS)N UGPCUUWZXRMCIJ-KKUMJFAQSA-N 0.000 claims description 2
- NUMFTVCBONFQIQ-DRZSPHRISA-N Gln-Ala-Phe Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O NUMFTVCBONFQIQ-DRZSPHRISA-N 0.000 claims description 2
- BTSPOOHJBYJRKO-CIUDSAMLSA-N Gln-Asp-Arg Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O BTSPOOHJBYJRKO-CIUDSAMLSA-N 0.000 claims description 2
- KVXVVDFOZNYYKZ-DCAQKATOSA-N Gln-Gln-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(O)=O KVXVVDFOZNYYKZ-DCAQKATOSA-N 0.000 claims description 2
- TWIAMTNJOMRDAK-GUBZILKMSA-N Gln-Lys-Asp Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O TWIAMTNJOMRDAK-GUBZILKMSA-N 0.000 claims description 2
- NKLRYVLERDYDBI-FXQIFTODSA-N Glu-Glu-Asp Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O NKLRYVLERDYDBI-FXQIFTODSA-N 0.000 claims description 2
- INGJLBQKTRJLFO-UKJIMTQDSA-N Glu-Ile-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCC(O)=O INGJLBQKTRJLFO-UKJIMTQDSA-N 0.000 claims description 2
- OCJRHJZKGGSPRW-IUCAKERBSA-N Glu-Lys-Gly Chemical compound NCCCC[C@@H](C(=O)NCC(O)=O)NC(=O)[C@@H](N)CCC(O)=O OCJRHJZKGGSPRW-IUCAKERBSA-N 0.000 claims description 2
- FMVLWTYYODVFRG-BQBZGAKWSA-N Gly-Asn-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN FMVLWTYYODVFRG-BQBZGAKWSA-N 0.000 claims description 2
- UFPXDFOYHVEIPI-BYPYZUCNSA-N Gly-Gly-Asp Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC(O)=O UFPXDFOYHVEIPI-BYPYZUCNSA-N 0.000 claims description 2
- TWTPDFFBLQEBOE-IUCAKERBSA-N Gly-Leu-Gln Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O TWTPDFFBLQEBOE-IUCAKERBSA-N 0.000 claims description 2
- OMDWJWGZGMCQND-CFMVVWHZSA-N Ile-Tyr-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N OMDWJWGZGMCQND-CFMVVWHZSA-N 0.000 claims description 2
- 102100034343 Integrase Human genes 0.000 claims description 2
- OGCQGUIWMSBHRZ-CIUDSAMLSA-N Leu-Asn-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O OGCQGUIWMSBHRZ-CIUDSAMLSA-N 0.000 claims description 2
- YKNBJXOJTURHCU-DCAQKATOSA-N Leu-Asp-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N YKNBJXOJTURHCU-DCAQKATOSA-N 0.000 claims description 2
- PJYSOYLLTJKZHC-GUBZILKMSA-N Leu-Asp-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O PJYSOYLLTJKZHC-GUBZILKMSA-N 0.000 claims description 2
- FOEHRHOBWFQSNW-KATARQTJSA-N Leu-Cys-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)N)O FOEHRHOBWFQSNW-KATARQTJSA-N 0.000 claims description 2
- KAFOIVJDVSZUMD-DCAQKATOSA-N Leu-Gln-Gln Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O KAFOIVJDVSZUMD-DCAQKATOSA-N 0.000 claims description 2
- DDVHDMSBLRAKNV-IHRRRGAJSA-N Leu-Met-Leu Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(O)=O DDVHDMSBLRAKNV-IHRRRGAJSA-N 0.000 claims description 2
- MVVSHHJKJRZVNY-ACRUOGEOSA-N Leu-Phe-Tyr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MVVSHHJKJRZVNY-ACRUOGEOSA-N 0.000 claims description 2
- VKVDRTGWLVZJOM-DCAQKATOSA-N Leu-Val-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O VKVDRTGWLVZJOM-DCAQKATOSA-N 0.000 claims description 2
- YNNPKXBBRZVIRX-IHRRRGAJSA-N Lys-Arg-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(O)=O YNNPKXBBRZVIRX-IHRRRGAJSA-N 0.000 claims description 2
- BXPHMHQHYHILBB-BZSNNMDCSA-N Lys-Lys-Tyr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BXPHMHQHYHILBB-BZSNNMDCSA-N 0.000 claims description 2
- QEVRUYFHWJJUHZ-DCAQKATOSA-N Met-Ala-Leu Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CC(C)C QEVRUYFHWJJUHZ-DCAQKATOSA-N 0.000 claims description 2
- SBSIKVMCCJUCBZ-GUBZILKMSA-N Met-Asn-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CCCNC(N)=N SBSIKVMCCJUCBZ-GUBZILKMSA-N 0.000 claims description 2
- OXIWIYOJVNOKOV-SRVKXCTJSA-N Met-Met-Arg Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCSC)C(=O)N[C@H](C(O)=O)CCCNC(N)=N OXIWIYOJVNOKOV-SRVKXCTJSA-N 0.000 claims description 2
- WYBVBIHNJWOLCJ-UHFFFAOYSA-N N-L-arginyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCCN=C(N)N WYBVBIHNJWOLCJ-UHFFFAOYSA-N 0.000 claims description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 claims description 2
- LLGTYVHITPVGKR-RYUDHWBXSA-N Phe-Gln-Gly Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O LLGTYVHITPVGKR-RYUDHWBXSA-N 0.000 claims description 2
- JTKGCYOOJLUETJ-ULQDDVLXSA-N Phe-Val-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CC1=CC=CC=C1 JTKGCYOOJLUETJ-ULQDDVLXSA-N 0.000 claims description 2
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 claims description 2
- KHRLUIPIMIQFGT-AVGNSLFASA-N Pro-Val-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O KHRLUIPIMIQFGT-AVGNSLFASA-N 0.000 claims description 2
- 108010003201 RGH 0205 Proteins 0.000 claims description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 2
- DSSOYPJWSWFOLK-CIUDSAMLSA-N Ser-Cys-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O DSSOYPJWSWFOLK-CIUDSAMLSA-N 0.000 claims description 2
- RNMRYWZYFHHOEV-CIUDSAMLSA-N Ser-Gln-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O RNMRYWZYFHHOEV-CIUDSAMLSA-N 0.000 claims description 2
- LALNXSXEYFUUDD-GUBZILKMSA-N Ser-Glu-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O LALNXSXEYFUUDD-GUBZILKMSA-N 0.000 claims description 2
- XNCUYZKGQOCOQH-YUMQZZPRSA-N Ser-Leu-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O XNCUYZKGQOCOQH-YUMQZZPRSA-N 0.000 claims description 2
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 claims description 2
- GDUZTEQRAOXYJS-SRVKXCTJSA-N Ser-Phe-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GDUZTEQRAOXYJS-SRVKXCTJSA-N 0.000 claims description 2
- QPPYAWVLAVXISR-DCAQKATOSA-N Ser-Pro-His Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CO)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O QPPYAWVLAVXISR-DCAQKATOSA-N 0.000 claims description 2
- HHJFMHQYEAAOBM-ZLUOBGJFSA-N Ser-Ser-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O HHJFMHQYEAAOBM-ZLUOBGJFSA-N 0.000 claims description 2
- WDFPMSHYMRBLKM-NKIYYHGXSA-N Thr-Glu-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O WDFPMSHYMRBLKM-NKIYYHGXSA-N 0.000 claims description 2
- HOVLHEKTGVIKAP-WDCWCFNPSA-N Thr-Leu-Gln Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HOVLHEKTGVIKAP-WDCWCFNPSA-N 0.000 claims description 2
- DCRHJDRLCFMEBI-RHYQMDGZSA-N Thr-Lys-Met Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(O)=O DCRHJDRLCFMEBI-RHYQMDGZSA-N 0.000 claims description 2
- BBPCSGKKPJUYRB-UVOCVTCTSA-N Thr-Thr-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(O)=O BBPCSGKKPJUYRB-UVOCVTCTSA-N 0.000 claims description 2
- FMOSEWZYZPMJAL-KKUMJFAQSA-N Tyr-Glu-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N FMOSEWZYZPMJAL-KKUMJFAQSA-N 0.000 claims description 2
- NKUGCYDFQKFVOJ-JYJNAYRXSA-N Tyr-Leu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NKUGCYDFQKFVOJ-JYJNAYRXSA-N 0.000 claims description 2
- GQVZBMROTPEPIF-SRVKXCTJSA-N Tyr-Ser-Asp Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GQVZBMROTPEPIF-SRVKXCTJSA-N 0.000 claims description 2
- VVZDBPBZHLQPPB-XVKPBYJWSA-N Val-Glu-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O VVZDBPBZHLQPPB-XVKPBYJWSA-N 0.000 claims description 2
- JVGHIFMSFBZDHH-WPRPVWTQSA-N Val-Met-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)O)N JVGHIFMSFBZDHH-WPRPVWTQSA-N 0.000 claims description 2
- UJMCYJKPDFQLHX-XGEHTFHBSA-N Val-Ser-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N)O UJMCYJKPDFQLHX-XGEHTFHBSA-N 0.000 claims description 2
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 claims description 2
- 230000024245 cell differentiation Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000012248 genetic selection Methods 0.000 claims description 2
- 108010079547 glutamylmethionine Proteins 0.000 claims description 2
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims description 2
- 108010050848 glycylleucine Proteins 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 108010091871 leucylmethionine Proteins 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 108010005942 methionylglycine Proteins 0.000 claims description 2
- 239000002751 oligonucleotide probe Substances 0.000 claims description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 claims description 2
- 108010026333 seryl-proline Proteins 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 108010061238 threonyl-glycine Proteins 0.000 claims description 2
- 108010073969 valyllysine Proteins 0.000 claims description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 101100342977 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) leu-1 gene Proteins 0.000 claims 1
- 210000004671 cell-free system Anatomy 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 29
- 241000283690 Bos taurus Species 0.000 description 28
- 235000018102 proteins Nutrition 0.000 description 25
- 102000004169 proteins and genes Human genes 0.000 description 25
- 241001494479 Pecora Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 18
- 229940079322 interferon Drugs 0.000 description 17
- 241000711975 Vesicular stomatitis virus Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 210000002993 trophoblast Anatomy 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 230000002357 endometrial effect Effects 0.000 description 3
- 210000004696 endometrium Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 238000010829 isocratic elution Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000001573 trophoblastic effect Effects 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101001026137 Cavia porcellus Glutathione S-transferase A Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241000252095 Congridae Species 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 101001026109 Gallus gallus Glutathione S-transferase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 235000019687 Lamb Nutrition 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001064 anti-interferon Effects 0.000 description 1
- 230000002521 anti-luteolytic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000003936 denaturing gel electrophoresis Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 230000001294 luteotrophic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Definitions
- the present invention relates to trophoblastin isoforms corresponding to Class II interferons endowed, inter alia, with anti-viral properties.
- WINTENBERGERTORRES described the identification of an anti-antioluteolytic component secreted by the embryo in the sheep, called trophoblast; he also established the protein nature of the trophoblast, which is thermolabile and sensitive to proteases; he further established that the period during which trophoblastin is secreted is very limited since its presence seems critical from day 12 of gestation only and is no longer detectable after days 21-23.
- the main polypeptides produced in the culture medium of conceptus of day 16 were identified by two-dimensional electrophoresis as having molecular weights of 22 to 26 kDa (by electrophoretic mobility in the presence of SDS) and a migration in a range of isoelectric points of 6.8 to 5.6; minor polypeptides of PM 40-50 and isoelectric points 6.2 to 7.4 have also been identified in the medium.
- This Publication also reports the hypothesis put forward that the study, after purification, of the proteins produced by the conceptus of bovines, should make it possible to elucidate their respective roles in the process of maintaining CL and to demonstrate that similar proteins produced by the sheep conceptus could be active in cattle.
- lapinant ⁇ -oTP-1 serum was used for the immunological characterization of proteins secreted by the bovine conceptus.
- the double immunodiffusion analysis by the Ouchterlony method with anti-oTP-1 serum, produced a double band against the unfractionated proteins secreted by bovine conceptus.
- One of these two bands has a partial identity both with purified oTP-1 and with the unfractionated proteins secreted by the ovine conceptus.
- Other experiments carried out in the presence of a radioactive amino acid, confirm the partial homology between the proteins produced by the ovine and bovine concepts and confirm the work of the MARTAL et al. Team. on transfers of inter-specific trophoblastic vesicles in sheep and cows, reported in J.
- oTP-1 comprises both cysteines in position 1, 29, 99 and 139 and a sequence Cys-Ala-Trp-Gly-Ile-Val-Val-Arg 139 146 that the 'found in most interferons - ⁇ .
- This Abstract also indicates that the Authors have demonstrated that oTP-1 has the antiviral and antiproliferative properties of an interferon, which leads them to suggest that oTP-1 not only corresponds to a signal of maternal recognition of gestation ( "maternai recognition of pregnancy") in sheep, but could also play the role of local immunomodulator.
- oTP-1 consists of 3 - 4 isoelectric variants of isoelectric points 5.5 - 5.8, with a molecular mass of 18 kDa and oTP-1 obtained by in vitro translation (pre -oTP-1) from polyadenylated RNA, consists of several polypeptides each of which has a molecular mass of the order of 21 kDa.
- oTPB or oT-1 or trophoblastin
- the sequence of 45 amino acids represented in this publication differs from the corresponding sequence represented in the publication of NATURE only by the fact that it comprises a Gln residue in position 5, an Arg residue in position 6, while the sequence of corresponding amino acid published in NATURE comprises in these two successive positions respectively an Arg residue and a Lys residue.
- the embryonic signal that constitutes trophoblastin is secreted at the time of differentiation of the embryo; its secretion begins on D 9, when the embryo is only an undifferentiated mass of cells and it disappears on the 22nd day of gestation, when the embryo is already formed.
- the deepening of knowledge relating to the protein designated under the name of trophoblastine would make it possible to lower the threshold of detection of the embryonic signal in question, which is of particular importance in the techniques of transfer and transplantation of embryos, in which it is essential to detect as early as possible if the transferred embryo is alive, and in which it would be even more favorable to be able to detect the viability of the embryos in synthetic media before transplantation.
- the subject of the present invention is isoforms of trophoblastin or of its embryonic analogs, characterized by a sequence of N-terminal amino acids which corresponds to a common general formula I: Cys-Tyr-Leu-Ser- (X) -Arg-Leu-Met-Leu-Asp-Ala- (U) -Glu-Asn-Leu
- T 1 isoform is characterized by an N-terminal amino acid sequence which corresponds to formula I 1 below:
- the T 2 isoform is characterized by an N-terminal amino acid sequence which corresponds to the form I 2 below:
- the T3 isoform is characterized by an N-terminal amino acid sequence which corresponds to formula I 3 below:
- the T4 isoform is characterized by an N-terminal amino acid sequence which corresponds to formula 14 below: Cys-Tyr- Leu-Ser-Gln-Arg-Leu-Met-Leu-Asp-Ala-Arg-Glu-Asn-
- T 5 is characterized by an N-terminal amino acid sequence which corresponds to formula I 5 below: Cys-Tyr-Leu-Ser-Gln-Arg-Leu-Met-Leu-Asp-Ala-Lys- Glu-Asn-Leu
- the present invention also relates to a process for the isolation of trophoblastin isoforms by high performance liquid phase chromatography (HPLC), characterized in that a culture medium obtained after a concept incubation is subjected of mammals for an appropriate time, to an anion exchange column chromatography balanced by a cationic buffer, then to the action of a salt gradient in a cationic buffer, in the space of an appropriate time interval, followed of an isocratic elution during which the isoforms are successfully collected.
- HPLC high performance liquid phase chromatography
- the conceptus collection medium intended to be cultured is constituted by an appropriate buffer devoid of serum albumin and containing polyvinylpyrrolidone at a concentration of approximately 0.05 % to 0.5% weight / volume.
- the concepts are cultured in a synthetic culture medium devoid of serum albumin and blood serum and containing the polyvinylpyrrolidone at a concentration of about 0.05% to
- the polyvinylpyrrolidone is preferably chosen from polyvinylpyrrolidones of high molecular weight, in order to promote its elimination by exclusion on a chromatography column or by insolubilization at acid pH.
- these isoforms each of which has a molecular weight of the order of 20 kDa, have an isoelectric point of approximately 5.4 for the Ti form, of approximately 5.3 for the T 2 form, d '' about 5.2 for the shape
- the present invention further relates to an agent having antiviral, antiproliferative, antitumor, immunological, immunomodulatory, inhibition of rejection, cell differentiation and inhibition of luteolysis activities at the start of gestation in mammals, as well that of genetic selection, characterized in that it consists of a class II interferon a, which is one of the isoforms of trophoblastin as identified by their N-terminal sequences of formulas I 1 , I 2 , I 3 , I 4 and Is or their mixtures.
- the present invention further relates to the nucleotide sequences of cDNA of each of the isoforms of trophoblastin, as well as the amino acid sequences. which are deduced from it.
- the nucleotide sequence of cDNA of the isoform T 2 consists of a polypeptide whose molecular weight is of the order of 23 kDa, corresponding to the precursor of trophoblastin, and which corresponds to formula II below:
- the present invention further relates to an oligodeoxynucleotide probe for the characterization of clones containing the cDNA of trophoblastin mRNA and its isoforms, which is deduced from the nucleotide sequence of the cDNA of one of the isoforms trophoblastin.
- such a probe it is characterized in that it corresponds to residues 34 to 43 of the N-terminal sequence of trophoblastin and corresponds to formula III below: 34 35 40 43
- TTT I which can be replaced by A, G or C.
- the invention naturally includes any equivalent probe deduced from the sequence of formula II or from the sequences of formulas I 1 , I 2 , I 3 , I 4 , Is suitable for characterize clones containing the trophoblastin mRNA cDNA or the gene thereof.
- the subject of the present invention is, moreover, a process for obtaining by cloning the cDNA of the mRNA of the isoforms of trophoblastin, characterized in that it comprises the following successive steps:
- the search for clones containing the cDNA of the trophoblastin mRNA is carried out using monospecific anti-trophoblastin immune serum.
- the search for said clones is carried out using an oligodeoxynucleotide probe deduced from the nucleotide sequence of the cDNA of one of the isoforms of trophoblastin, and in particular of the oligonucleotide probe of formula III above, by hybridization of said clones with said probe, followed by isolation of inserts of appropriate size and subcloning into an appropriate plasmid (in particular pUC18) to determine that one of the clones s' hybrid with a single 1.1 kb RNA coding for a polypeptide of approximately 23 kDa corresponding to the precursor of trophoblastin and that the other of the clones hybridizes with the mRNA corresponding to the cDNA of one of the isoforms trophoblastin.
- an oligodeoxynucleotide probe deduced from the nucleotide sequence of the cDNA of one of the isoforms of trophoblastin, and in particular of the
- the present invention also relates to a kit for detecting an embryonic signal to control the viability of an embryo at an early stage of its development, characterized in that it comprises, as detection agent, at least one trophoblastin isoform of formula I above.
- the present invention further encompasses the application of the trophoblastin isoforms according to the present invention as agents for protecting embryos during their transfer into the uterus of a recipient mammal, and as agents therapeutic, in particular as antiviral, antiproliferative, antitumour, immunomodulatory agents, in veterinary or human medicine.
- Trophoblastin is the first isolated class II ⁇ interferon naturally expressed in mammalian tissue. So far, the rare known class II ⁇ interferons (bovine, human, equine, porcine) have only been demonstrated using molecular DNA probes or by expression in bacterial systems. As a result, the properties of class II ⁇ interferons are little known. In addition, the structure of a natural interferon can differ significantly by its glycosylated parts, from interferons obtained by genetic engineering. Trophoblastine has the originality for an interferon not to be secreted following a viral infection. In addition, it is produced in an exceptionally high quantity compared to that of all naturally expressed interferons.
- the embryos are eliminated and the culture medium is centrifuged at 10,000 g for 20 minutes at 4 ° C., then dialyzed and concentrated against 50 mM TRIS / HCl buffer pH 6.00.
- Trophoblastin is purified to a high degree of purity by high performance liquid phase chromatography (HPLC) on a DEAE 5 PW column 7.5 mm in diameter and 75 mm in length, eluted at a flow rate of 0.5 ml / min by a gradient from 0 to 0.15 M KCl in a 0.05 M Tris HCl buffer pH 6.00, within 40 min, followed by an isocratic elution at 0.15 M KCl in the same buffer .
- HPLC high performance liquid phase chromatography
- the trophoblast is purified to a high degree of purity by high performance liquid chromatography (HPLC) on a column, semi-preparative anion exchange DEAE-5 PW of 21.5 mm in diameter over 150 mm in length, eluted with a flow rate of 4 ml / min, by a gradient from 0 to 0.15 M KCl in a 0.05 M Tris-HCl pH 6.00 buffer, within 60 minutes, followed by isocratic elution at 0.15 M KCl in the same buffer.
- HPLC high performance liquid chromatography
- Figure 1 attached shows the isolation of the polypeptides T 1 , T 2 , T 3 in the isocratic part of the gradient close to 0.5 M KCl.
- Purified trophoblastin has an apparent molecular weight of 20 kDa and an isoelectric point of approximately 5.3. It specifically binds to endometrial membrane receptors, which demonstrates the maintenance of its biological activity after the purification steps.
- the uterine receptor for this embryonic signal exists at the end of the luteal phase of the oestrian cycle while the embryo is absent.
- the five trophoblastin isoforms, T 1 , T 2 , T 3 , T 4 , T 5 , isolated in accordance with the present invention, are variants thereof, as demonstrated by the sequencing of the N-terminal end of these five proteins, as shown in Formulas I, I 1 , I 2 and I 3 , I 4 , I 5 above.
- ovine trophoblastin possesses the antiviral activity of interferons, in the presence of bovine MDBK cells infected with bovine vesicular stomatitis virus (VSV).
- VSV bovine vesicular stomatitis virus
- the cells were infected with 100 PFU of VSV (Serotype Indiana) in 0.2 ml of MEM + 2% SVF, then finally covered with 3 ml of MEM + 2% VSF containing 0.6% of agarose, with which they were incubated for another 24 hours at 37 ° C.
- the viral plaques were counted after staining with crystal violet and the dilution of the protein causing 50% inhibition of the VSV plaques was determined.
- the titers expressed in international units of human IFN (iu / ml) were deduced from the titer of a standard laboratory IFN included in these tests and calibrated with respect to the human IFN reference Ga23-902-530 (NIH Bethesda, Md, 12,000 iu / ml).
- the specific activity of isoforms 1, 2, 3 purified by HPLC is respectively 0.6 ⁇ 10 ei / mg of protein, 0.8 ⁇ 10 ei / mg of protein and 0.7 ⁇ 10 s iu / mg of protein in the presence of MDBK and VSV cells (of. Figure 6 attached).
- the antiviral activity of two pools of culture media for 16-day-old sheep embryos is between 0.25 and 0.68 ui / mg trophoblastin.
- the differential antiviral activity was measured in cells of different species by inhibition of the effect exerted on VSV carried by plates as described above.
- the results obtained are collated in Table I below, in which MM6 designates a sheep cell line established from fetal lamb fibroblasts; PD-5 is a pig kidney cell line; WISH is a human cell line and L 929 is a murine cell line.
- the three purified isoforms were diluted to give the same antiviral titer on the MDBK cells.
- This Table shows that the three isoforms have the same relative activity pattern, at least on bovine, ovine, porcine and human cells, isoform 2 being more active on murine cells than the other two isoforms, of a factor of about 9 to 27.
- trophoblastin not only exhibits strong structural homology with interferons, as indicated in the aforementioned FEBS LETTERS Publication, but it also has the antiviral activity characteristic of all families of interferons.
- seroneutralization the inventors have been able to confirm that the ovine trophoblastin is indeed a class II ⁇ interferon: a class I anti-interferon ⁇ immune serum does not recognize trophoblastin and conversely a monospecific anti-trophoblastin immune serum does not recognize ⁇ interferons class I.
- Table II illustrates the seroneutralization of viral activity in the presence of interferon (IFN) and anti-IFN immune serum.
- IFN interferon
- VSV vesicular stomatitis virus
- the immuniser used is anti-T rabbit immuniser (mixture of isoforms T 1 , T 2 , T 3 ).
- EXAMPLE 3 CLONING OF TROPHOBLASTIN.
- Obtaining clones containing the cDNA for trophoblastin mRNA comprises the following steps. 1. Isolation of total poly (A) + embryonic RNAs, using the guanidine isothiocyanate method from 16-day-old sheep embryos (CATHALA et al., 1983). In order to have a "negative" control corresponding to a late stage during which trophoblastin is no longer secreted, mRNAs were also isolated from embryos 29 days old. After purification on an affinity column (oligo dT cellulose), approximately 50 to 60 ⁇ g of poly (A) + RNA were obtained from around twenty 16-day-old embryos, removed surgically.
- affinity column oligo dT cellulose
- trophoblastin precursor and quantification of the corresponding mRNA.
- the biological activity of embryonic poly (A) + RNA was measured by in vitro translation in two acellular systems (reticulocyte lysate and wheat germ) in the presence of 35 S-methionine. In these two cases, the amount of trophoblastin synthesized was estimated by SDS electrophoresis, followed by immunoprecipitation, respectively using a monospecific antitrophoblastin antiserum prepared by the inventors. Under these conditions, a polypeptide with an apparent molecular weight of ⁇ 23 kDa was detected; it corresponds to the precursor of trophoblastin and represents approximately 1 to 2% of the total mRNAs.
- the cDNAs were synthesized according to the method of GUBLER and HOFFMAN (1983) which makes it possible to obtain cDNAs of length close to that of the mRNAs. After addition of EcoRI "linkers", these cDNAs were inserted respectively into the EcoRI sites of a plasmid vector (pUC8) and of an expression vector, the bacteriophage Lambda gt 11 ( ⁇ gtll), then cloned into the strains ( DH5 and Y1088) of colibacilli (Esche ⁇ chia coli). The plasmid and phage banks contained respectively 4.10 5 and 1.2.10 6 recombinants per ⁇ g of DNA.
- Mdp 7 hybridized with a single 1.1 kb mRNA (Northern-blot technique); this size was compatible with that of an mRNA coding for a polypeptide of ⁇ 23 kDa (precursor of the trophoblast). This is the reason why further analysis of these clones was undertaken.
- IFN ⁇ lI class II ⁇ interferons
- the amino acid sequence of isoform 2 determined by peptide hydrolysis is strictly identical to cDNA ( Figure 5). No N-glycosylation site (ASN-X-THR or SER) is observed. Furthermore, the region corresponding to the signal peptide has a homology of more than 95% at the nucleotide level and 100% at the level of the primary structure with that of bovine class II interferon ⁇ (CAPON, SHEPARD and GOEDDEL, ( MOL. CELL. BIOL. (1985), 5, 768-779), which suggests that these two molecules could derive from a common ancestral gene.
- CAPON, SHEPARD and GOEDDEL bovine class II interferon ⁇
- bovine class I IFN ⁇ 64% with bovine class I IFN ⁇ .
- bovine class II IFN ⁇ 71% (and 56% with human IFN ⁇ lI), while it is only 48% with bovine class I IFN ⁇ .
- trophoblastin corresponds to a class II ⁇ embryonic interferon.
- a quantitative method for detecting the ovine trophoblast has been developed by the inventors. It consists of a radioimmunological assay by competition, using two antibodies, under the following conditions: the ovine trophoblastin used for labeling with Iodine 125 and for the calibration curves, is derived from the purification by HPLC chromatography of culture media sheep embryos. An anti-trophoblastin antiserum after immunization of rabbits is used at a final dilution of 1 / 360,000; it binds 35% radioactive trophoblastin under the dosage conditions established by the Inventors.
- this method makes it possible to detect 15 pg of trophoblastin in 100 ⁇ l of sample to be tested.
- ⁇ represent the culture medium for sheep embryos.
- - Specificity of the assay there is no cross-immunoreactivity with porcine interferons, secretion products from bovine, porcine, rabbit embryos and serum compounds.
- this assay it is possible to follow the evolution of the secretion of trophoblastin in vivo and in vitro.
- the sensitivity of the assay makes it possible to detect small amounts of trophoblastin secreted by sheep and goat embryos at very early stages (20ng / embryo in sheep perfusates at 11 days of gestation, 1 ⁇ g / day for an 11-day cultivated embryo in vitro).
- the cDNA of the trophoblastin isoforms which are the subject of the present invention or of their analogs can, moreover, be used for all the productions of class II ⁇ interferons by genetic engineering methods (bacterial, cellular expression , genetic engineering or through transgenic animals).
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8803591A FR2628744B1 (fr) | 1988-03-18 | 1988-03-18 | Isoformes de la trophoblastine, nouveaux interferons constitues par lesdites isoformes, leurs procedes d'obtention et leurs applications |
FR8803591 | 1988-03-18 | ||
US30420989A | 1989-01-31 | 1989-01-31 | |
US304209 | 2002-11-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0400083A1 true EP0400083A1 (de) | 1990-12-05 |
Family
ID=26226567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19890903762 Withdrawn EP0400083A1 (de) | 1988-03-18 | 1989-03-17 | Trophoblastin-isoformen, durch diese isoformen konstituierte interferone, verfahren zu deren erhalt und deren verwendung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0400083A1 (de) |
AU (1) | AU638207B2 (de) |
WO (1) | WO1989008706A1 (de) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0367063A1 (de) * | 1988-10-26 | 1990-05-09 | The Curators Of The University Of Missouri | Isolation und Klonierung von cDNA für das für Rindertrophoblast kodierende Gen |
AU656353B2 (en) * | 1990-11-29 | 1995-02-02 | Institut National De La Recherche Agronomique (Inra) | New variants derived from interferons of type I, production process thereof and their applications |
FR2669824B1 (fr) * | 1990-11-29 | 1995-02-24 | Agronomique Inst Nat Rech | Utilisation de variants des interferons alpha pour l'obtention de medicaments. |
FR2669931B1 (fr) * | 1990-11-29 | 1995-03-31 | Transgene | Nouveaux variants derives des interferons-alpha et leur procede de production. |
US5540923A (en) * | 1991-12-06 | 1996-07-30 | Landsforeningen Til Kraeftens Bekaemplse | Interferon proteins |
TW585911B (en) * | 1992-10-30 | 2004-05-01 | Univ Florida | Ovine and bovine interferon TAU, compositions thereof and pharmaceutical uses thereof |
EP0700523A1 (de) * | 1993-05-21 | 1996-03-13 | Brigham & Women's Hospital, Inc. | Embryotoxische faktoren |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0174143B1 (de) * | 1984-08-27 | 1989-11-08 | Genentech, Inc. | Verschiedenartige Familie von menschlichen Leukozyten-Interferonen, Zusammensetzungen, die diese enthalten, Verfahren zu ihrer Herstellung, sowie DNA und transfektierte Wirte hierfür |
-
1989
- 1989-03-17 EP EP19890903762 patent/EP0400083A1/de not_active Withdrawn
- 1989-03-17 WO PCT/FR1989/000116 patent/WO1989008706A1/fr not_active Application Discontinuation
- 1989-03-17 AU AU32953/89A patent/AU638207B2/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
See references of WO8908706A1 * |
Also Published As
Publication number | Publication date |
---|---|
AU3295389A (en) | 1989-10-05 |
AU638207B2 (en) | 1993-06-24 |
WO1989008706A1 (fr) | 1989-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ohmichi et al. | Binding sites for interleukin-6 in the anterior pituitary gland | |
Van der Linde-Sipman et al. | Generalized AA-amyloidosis in Siamese and Oriental cats | |
CA2158047C (en) | Allergenic protein and peptides from house dust mite and uses therefor | |
EP0394424B1 (de) | Peptide und polypeptide stammend von den submaxillaren drüsen der ratte, deren entsprechende monoklonale und polyklonale antikörper entsprechende hybridomen und verwendung dieser verbindungen in der diagnose bei bestimmungen und für pharmazeutische zwecke | |
Diana et al. | Co-localization of interleukin-1 receptor type I and interleukin-1 receptor antagonist with vasopressin in magnocellular neurons of the paraventricular and supraoptic nuclei of the rat hypothalamus | |
US6238915B1 (en) | Mutant human growth hormones and their uses | |
JPH034796A (ja) | T細胞増殖促進因子 | |
Shanley et al. | Regulatory effects of endogenous interleukin-1 receptor antagonist protein in immunoglobulin G immune complex-induced lung injury. | |
AU597268B2 (en) | Interferon-induced (2'-5') oligo A synthetase gene, mRNA, cDNA and enzymes having (2'-5') oligo A synthetase activity | |
WO1989008706A1 (fr) | Isoformes de la trophoblastine, nouveaux interferons constitues par lesdites isoformes, leurs procedes d'obtention et leurs applications | |
Imakawa et al. | Temporal expression of type I interferon receptor in the peri-implantation ovine extra-embryonic membranes: demonstration that human IFNα can bind to this receptor | |
Steinbach et al. | Molecular cloning and characterization of markers and cytokines for equid myeloid cells | |
Winkler et al. | Chemical and immunologic characterization of a β2-microglobulin-like protein isolated from chicken sera | |
FR2550943A1 (fr) | Vaccin synthetique contre le cholera | |
FR2657014A1 (fr) | Recepteur humain de la tsh. sequence codant pour ce recepteur. | |
US5051371A (en) | Modified β2 -microglobulin | |
Heller et al. | Chicken-embryo fibroblasts produce two types of interferon upon stimulation with Newcastle disease virus | |
EP0763111B1 (de) | Epil/plazentin | |
FR2628744A1 (fr) | Isoformes de la trophoblastine, nouveaux interferons constitues par lesdites isoformes, leurs procedes d'obtention et leurs applications | |
US7319933B2 (en) | Gene transcription assay method | |
Prabhakar et al. | Serum protein of 135-kDa molecular weight-a molecular signal for cardiac hypertrophy | |
Horisberger et al. | Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid | |
JPH05500160A (ja) | T細胞増殖促進因子 | |
JP2006514699A (ja) | 肝疾患に対するccケモカイン変異体の使用 | |
JPH1156378A (ja) | 変異型ヒト成長ホルモンとその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19900912 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LI LU NL SE |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GUILLOMOT, MICHEL Inventor name: HUET, JEAN-CLAUDE Inventor name: MARTAL, JACQUES Inventor name: CHARPIGNY, GILLES Inventor name: PERNOLLET, JEAN-CLAUDE Inventor name: REINAUD, PIERRETTE Inventor name: CHARLIER, MADIA Inventor name: GAYE, PIERRE |
|
17Q | First examination report despatched |
Effective date: 19930713 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19931124 |